RADOCHA, Jakub, Vladimír MAISNAR, Luděk POUR, Ivan ŠPIČKA, Jiří MINAŘÍK, Lenka SZELIGOVÁ, Petr PAVLÍČEK, Alexandra JUNGOVÁ, Marta KREJČÍ, Tomáš PIKA, Jan STRAUB, Lucie BROŽOVÁ, Lukáš STEJSKAL, Adriana HEINDORFER, Pavel JINDRA, Petr KESSLER, Peter MIKULA, Michal SYKORA, Marek WRÓBEL, Jiří JARKOVSKÝ and Roman HAJEK. Validation of multiple myeloma risk stratification indices in routine clinical practice: Analysis of data from the Czech Myeloma Group Registry of Monoclonal Gammopathies. Cancer Medicine. Houston: John Wiley & Sons Ltd., 2018, vol. 7, No 8, p. 4132-4145. ISSN 2045-7634. Available from: https://dx.doi.org/10.1002/cam4.1620.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Validation of multiple myeloma risk stratification indices in routine clinical practice: Analysis of data from the Czech Myeloma Group Registry of Monoclonal Gammopathies
Authors RADOCHA, Jakub (203 Czech Republic, guarantor), Vladimír MAISNAR (203 Czech Republic), Luděk POUR (203 Czech Republic, belonging to the institution), Ivan ŠPIČKA (203 Czech Republic), Jiří MINAŘÍK (203 Czech Republic), Lenka SZELIGOVÁ (203 Czech Republic), Petr PAVLÍČEK (203 Czech Republic), Alexandra JUNGOVÁ (203 Czech Republic), Marta KREJČÍ (203 Czech Republic, belonging to the institution), Tomáš PIKA (203 Czech Republic), Jan STRAUB (203 Czech Republic), Lucie BROŽOVÁ (203 Czech Republic, belonging to the institution), Lukáš STEJSKAL (203 Czech Republic), Adriana HEINDORFER (203 Czech Republic), Pavel JINDRA (203 Czech Republic), Petr KESSLER (203 Czech Republic), Peter MIKULA (203 Czech Republic), Michal SYKORA (203 Czech Republic), Marek WRÓBEL (203 Czech Republic), Jiří JARKOVSKÝ (203 Czech Republic, belonging to the institution) and Roman HAJEK (203 Czech Republic).
Edition Cancer Medicine, Houston, John Wiley & Sons Ltd. 2018, 2045-7634.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30204 Oncology
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
Impact factor Impact factor: 3.357
RIV identification code RIV/00216224:14110/18:00104185
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1002/cam4.1620
UT WoS 000441430100054
Keywords in English Czech Myeloma Group Registry; monoclonal gammopathies; multiple myeloma; overall survival; real-world; risk stratification
Tags 14110212, 14119612, rivok
Tags International impact, Reviewed
Changed by Changed by: Soňa Böhmová, učo 232884. Changed: 11/2/2019 15:54.
Abstract
This study used data from the Czech Myeloma Group Registry of Monoclonal Gammopathies to validate the International Myeloma Working Group (IMWG) and revised International Staging System (R-ISS) indices for risk stratification in patients with multiple myeloma (MM) in clinical practice. Patients were included if they had symptomatic MM, complete data allowing R-ISS and IMWG staging (including cytogenetic information regarding t(4;14), t(14;16), and del(17p)), and key parameters for treatment evaluation. Median overall survival (OS) in included patients (n = 550) was 47.7 (95% CI: 39.5-55.9) and 46.2 (95% CI: 38.9-53.5) months from diagnosis and initiation of first-line therapy, respectively. Patients categorized as higher vs lower risk had reduced survival; median OS from diagnosis was 35.4 (95% CI: 30.5-40.3) vs 58.3 (95% CI: 53.8-62.9) months in high-risk vs other patients (IMWG; P = .001) and 34.1 (95% CI: 30.2-38.0) vs 47.2 (95% CI: 43.4-51.0) months in Stage III vs Stage II patients (R-ISS; P < .001). In conclusion, IMWG and R-ISS risk stratification indices are applicable to patients with MM in a real-world setting.
PrintDisplayed: 21/7/2024 03:49